John W. Moroney
Expertise in
12
conditions

Dr. John W. Moroney

Obstetrics and Gynecology
14290 S. La Grange Rd., 
Orland Park, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
12
conditions
14290 S. La Grange Rd., 
Orland Park, IL 

Overview

John Moroney is an Obstetrics and Gynecologist practicing medicine in Orland Park, Illinois.

Dr. Moroney is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Gastrostomy, and Bladder Reconstruction.

Dr. Moroney is board certified in Gynecologic Oncology, American Board Of Obstetrics Gynecology, and Practicing Since2002. He is actively involved in clinical research, co-authoring 24 peer reviewed articles and participating in 20 clinical trials. Dr. Moroney is currently accepting new patients.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in IL

Board Certifications

Gynecologic Oncology
American Board Of Obstetrics Gynecology
Practicing Since2002

Fellowships

U.T.M.D Anderson Cancer Center (Gynecological Oncology)

Hospital Affiliations

Uchicago Medicine Adventhealth Hinsdale
The University Of Chicago Medical Center
Uchicago Medicine Adventhealth Bolingbrook
Uchicago Medicine Adventhealth La Grange
UChicago Medicine Faculty Physicians

Languages Spoken

English
Turkish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

UChicago Medicine Orland Park
14290 S. La Grange Rd., Orland Park, IL 60462
Other Locations
Endeavor Health Medical Group
880 W. Central Rd., Suite 5000, Arlington Heights, IL 60005

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Recruiting
Publish Date: April 01, 2026
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab, Ipatasertib, Talazoparib, Trastuzumab Emtansine, Tiragolumab
Study Phase: Phase 1/Phase 2
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Tremelimumab
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Enrollment Status: Terminated
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin
Study Phase: Phase 1/Phase 2
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Pilot, Multicenter, Single Arm, Open Label, Surgical Window of Opportunity Study of Abemaciclib and Letrozole for Endometrioid Adenocarcinoma of the Endometrium
A Pilot, Multicenter, Single Arm, Open Label, Surgical Window of Opportunity Study of Abemaciclib and Letrozole for Endometrioid Adenocarcinoma of the Endometrium
Enrollment Status: Completed
Publish Date: October 20, 2025
Intervention Type: Drug, Procedure
Study Drugs: Abemaciclib, Letrozole
Study Phase: Early Phase 1
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Afuresertib
Study Phase: Phase 2
View 9 Less Clinical Trials

24 Total Publications

Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.
Journal: Gynecologic oncology
Published: April 19, 2026
Similar Doctors
Expertise in
10
conditions
Dr. Gary H. Altwerger
Obstetrics and Gynecology
Expertise in
10
conditions
Dr. Gary H. Altwerger
Obstetrics and Gynecology
Referral may be required

UChicago Medicine Orland Park

14290 S. La Grange Rd., 
Orland Park, IL 
 (0.1 miles away)
888-824-0200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gary Altwerger is an Obstetrics and Gynecologist practicing medicine in Orland Park, Illinois. Dr. Altwerger is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Hormone Replacement Therapy (HRT), and Hysterectomy.

Expertise in
16
conditions
Dr. Sudarshan K. Sharma
Obstetrics and Gynecology
Expertise in
16
conditions
Dr. Sudarshan K. Sharma
Obstetrics and Gynecology
Referral may be required

UChicago Medicine Duchossois Center For Advanced Medicine - Hyde Park

5758 S. Maryland Ave., 
Chicago, IL 
 (16.9 miles away)
888-824-0200
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sudarshan Sharma is an Obstetrics and Gynecologist practicing medicine in Chicago, Illinois. Dr. Sharma is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Oophorectomy, and Lymphadenectomy. Dr. Sharma is currently accepting new patients.

Expertise in
40
conditions
Dr. Alfred S. Guirguis
Obstetrics and Gynecology | Oncology
Expertise in
40
conditions
Dr. Alfred S. Guirguis
Obstetrics and Gynecology | Oncology
Referral may be required
Before you request

Affiliated Oncologists, LLC

3825 Highland Ave., Suite 307, 
Downers Grove, IL 
 (15.2 miles away)
708-422-3242
Languages Spoken:
English, Arabic, Lithuanian, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Alfred Guirguis is an Obstetrics and Gynecologist and an Oncologist practicing medicine in Downers Grove, Illinois. Dr. Guirguis is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Hernia Surgery, and Oophorectomy. Dr. Guirguis is board certified in American Board Of Obstetrics And Gynecology and American Board Of Obstetrics & Gynecology, Gynecologic Oncology. Dr. Guirguis is currently accepting new patients.

Frequently Asked Questions about Dr. John W. Moroney

How do I make an appointment with Dr. John W. Moroney?

You can book an appointment with Dr. John W. Moroney by calling their office at 888-824-0200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John W. Moroney a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John W. Moroney is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John W. Moroney specialize in?

While Dr. John W. Moroney is a Obstetrics and Gynecology, they have specific expertise in Endometrial Cancer, Ovarian Cancer, and Sertoli-Leydig Cell Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. John W. Moroney participate in research or clinical trials?

Yes. Dr. John W. Moroney has published 24 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. John W. Moroney's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John W. Moroney accept my insurance?

Dr. John W. Moroney accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 888-824-0200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moroney's expertise for a condition
ConditionClose
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile